StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Brainstorm Cell Therapeutics Trading Down 6.1 %
Shares of NASDAQ BCLI opened at $0.34 on Thursday. The company has a market cap of $23.72 million, a price-to-earnings ratio of -1.06 and a beta of 0.43. Brainstorm Cell Therapeutics has a 12 month low of $0.13 and a 12 month high of $2.18. The stock has a 50-day moving average price of $0.46 and a two-hundred day moving average price of $0.41.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. On average, sell-side analysts predict that Brainstorm Cell Therapeutics will post -0.28 earnings per share for the current year.
Institutional Trading of Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Read More
- Five stocks we like better than Brainstorm Cell Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MarketBeat Week in Review – 6/24 – 6/28
- What Investors Need to Know About Upcoming IPOs
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.